公开(公告)号：US20240288436A1

公开(公告)日：2024-08-29

申请号：US18571623

申请日：2022-06-16

申请人： KOREA ATOMIC ENERGY RESEARCH INSTITUTE ,  INDUSTRY ACADEMY COOPERATION FOUNDATION OF SEJONG UNIVERSITY

发明人： In Gyu KIM ,  Chun Jeih RYU ,  Min Kyu KIM ,  Rae Kwon KIM ,  Hwangseo PARK ,  Mun Ju CHOI ,  Yeon Jee KAHM ,  Byung Chul SHIN ,  U Hee JUNG

IPC分类号： G01N33/574 ,  C07K16/28

CPC分类号： G01N33/57492 ,  C07K16/2896 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/92 ,  C07K2317/94

摘要： The present invention relates to an anti-TM4SF4 (TransMembrane 4 Superfamily Member 4) humanized antibody and use thereof. The anti-TM4SF4 humanized antibody of present invention has high affinity for binding specifically to TM4SF4 while exhibiting low immunogenicity in humans, and thus can be advantageously used to detect TM4SF4 or to target cancer cells and cancer stem cells that overexpress TM4SF4.

公开(公告)号：US20240102019A1

公开(公告)日：2024-03-28

申请号：US17768906

申请日：2020-10-14

申请人： KOREA ATOMIC ENERGY RESEARCH INSTITUTE

发明人： In Gyu KIM ,  Rae Kwon KIM ,  Yeon Jee KAHM

IPC分类号： C12N15/113 ,  A61P35/00 ,  C07K16/28

CPC分类号： C12N15/1138 ,  A61P35/00 ,  C07K16/28 ,  C07K2317/76 ,  C12N2310/14 ,  C12N2320/31

摘要： The present invention relates to a composition for inhibiting the growth of cancer stem cells and a use thereof. When treated with the EMP3 inhibitor, cancer stem cells expressing ALDH1 decrease in self-renewal potential, invasiveness, and migration ability and thus are restrained from growing, whereby cancer having stemness properties, which are resistant to conventional anticancer therapies, can be effectively treated.

公开(公告)号：US20230002485A1

公开(公告)日：2023-01-05

申请号：US17299156

申请日：2020-12-04

申请人： KOREA ATOMIC ENERGY RESEARCH INSTITUTE

发明人： In Gyu KIM ,  Rae Kwon KIM ,  Jai Ha LEE ,  Chang Kyu HEO ,  Yeon Jee KAHM ,  Byung Chul SHIN ,  Eun Wie CHO ,  Chun Jeih RYU ,  Min Kyu KIM ,  Mun Ju CHOI

IPC分类号： C07K16/28 ,  A61P35/00 ,  A61P11/00

摘要： The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.